- ITM Isotope Technologies Munich SE and Ariceum Therapeutics have entered into a supply agreement for non-carrier-added (n.c.a.) Actinium-225 to support Ariceum’s cancer therapy pipeline.
- Actineer, ITM’s joint venture, will produce and supply Ac-225, advancing the development of novel radiopharmaceutical treatments for aggressive cancers.
ITM Isotope Technologies Munich SE (ITM) has announced a supply agreement with Ariceum Therapeutics to deliver non-carrier-added (n.c.a.) Actinium-225 (Ac-225) for use in the development of Ariceum’s novel radiopharmaceutical therapies. The agreement is set to support Ariceum’s pipeline, which includes its lead drug, satoreotide, aimed at treating aggressive, hard-to-treat cancers.
The Ac-225, produced by ITM’s joint venture company Actineer™ Inc, will play a critical role in Ariceum’s drug development process. Actineer is dedicated to expanding its supply chain and producing industrial-scale quantities of Ac-225 using Radium-226 (Ra-226) irradiated in cyclotrons. The agreement reflects both companies’ commitment to meeting the growing global demand for this rare medical radioisotope, which is essential in the field of targeted radiopharmaceutical therapies (RPT).
Ac-225 is a sought-after resource in cancer treatment due to its ability to emit high-energy alpha particles with a short tissue penetration range, allowing precise tumour cell targeting. However, its natural scarcity and complex manufacturing process have led to shortages, threatening the development of novel treatments for difficult cancers.
Dr. Andrew Cavey, CEO of ITM, expressed enthusiasm about the partnership: “We value our partnership with Ariceum, which marks a significant step forward in advancing our mission to provide this critical medical radioisotope to the radiopharmaceutical industry.” He highlighted ITM’s expertise in radiopharmaceutical production, particularly in Lutetium-177, and its application to Ac-225 via Actineer.
Ariceum’s CEO, Manfred Rüdiger, also emphasised the importance of the agreement, stating: “Securing a reliable and plentiful supply of n.c.a. Ac-225 is critical to our efforts in developing innovative cancer treatments with our pipeline of novel targeted radiopharmaceuticals.”